ALK and non-small cell lung carcinoma: A phase I study of ceritinib showed an overall response rate of 56% in ALK fusion-positive NSCLC patients who had progressed on crizotinib (NCT01283516) and the compound subsequently received FDA approval for this indication [124,125].